Cantor Fitzgerald Maintains Overweight on Disc Medicine, Raises Price Target to $170

Cantor Fitzgerald analyst Kristen Kluska has maintained an Overweight rating on Disc Medicine (NASDAQ: IRON) and raised the price target from $125 to $170. This adjustment reflects a positive outlook on the company's performance.